[144] United Therapeutics Corp SEC Filing

Rhea-AI Filing Summary

United Therapeutics Corp (UTHR) Form 144: This notice shows that Martine Rothblatt proposes to sell 4,000 common shares through TD Securities (125 Park Ave, 20th Floor, New York) with an aggregate market value of $1,588,904.00, scheduled approximately for 09/11/2025. The issuer has 45,230,000 shares outstanding, per the filing.

The shares were originally acquired on 03/15/2016 under an executive deferred compensation arrangement from Martine Rothblatt, with 294,000 shares shown as acquired then. The filing also reports recent sales by the same person in the past three months: 8,000 shares sold on 09/09/2025 for $3,188,374.33 and 4,000 shares sold on 09/10/2025 for $1,594,872.82. The filer attests there is no undisclosed material adverse information.

Positive

• Form 144 filed and broker identified, indicating compliance with Rule 144 sales notification requirements.
• Source of shares disclosed (executive deferred compensation from 03/15/2016), supporting legitimacy of the holdings.

Negative

• Recent insider sales total 12,000 shares sold on 09/09 and 09/10/2025 with combined gross proceeds > $4.7 million, which may prompt investor scrutiny.
• Proposed additional sale of 4,000 shares on 09/11/2025, extending the sequence of insider dispositions.

Insights

Securities Analyst

TL;DR: Insider sales of 12,000 shares over three days are disclosed; not clearly material to company fundamentals.

The filing documents open-market dispositions by a significant insider, Martine Rothblatt, totaling 12,000 shares sold on 09/09 and 09/10/2025, and a proposed sale of 4,000 shares on 09/11/2025 via TD Securities. While the gross proceeds reported are substantial in absolute dollars (> $6.3 million across reported sales), the disclosed outstanding share count of 45.23 million suggests these transactions represent a small percentage of the float. There is no accompanying financial or operational information to imply a change in company outlook; this is a liquidity event by the insider rather than a disclosed strategic or operational development.

Corporate Governance Expert

TL;DR: Filing indicates compliance with Rule 144 and an attestation of no undisclosed material information.

The Form 144 shows the seller relied on Rule 144 notice procedures and includes a representation that no material nonpublic information is known to the seller. The source of the shares is identified as an executive deferred compensation arrangement dating to 2016, which supports the legitimacy of the transfer path. From a governance perspective, timely disclosure and use of a registered broker are positive controls; however, concentrated insider selling over consecutive days is a governance signal investors often monitor for context.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	TD SECURITIES (USA) LLC 125 PARK AVE, 20TH FLOOR NEW YORK NY 10017	4000	1588904.00	45230000	09/11/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	03/15/2016	Executive Deferred Compensation	Martine Rothblatt			294000	03/15/2016	Shares exercised via vested options and payment made via common shares

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/09/2025	8000	3188374.33
Martine Rothblatt 1000 Spring Street Silver Springs MD 20910	Common	09/10/2025	4000	1594872.82

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

Who is selling shares according to the UTHR Form 144?

The seller is Martine Rothblatt, listed as the person for whose account the securities are to be sold.

How many shares is the Form 144 proposing to sell and when?

The notice proposes sale of 4,000 common shares with an approximate sale date of 09/11/2025.

What broker is handling the proposed UTHR sale?

The broker named is TD Securities (USA) LLC, 125 Park Ave, 20th Floor, New York, NY 10017.

Were there any recent sales by the same person in the past three months?

Yes. The filing reports 8,000 shares sold on 09/09/2025 for $3,188,374.33 and 4,000 shares sold on 09/10/2025 for $1,594,872.82.

How were the shares originally acquired?

The shares were acquired on 03/15/2016 under an executive deferred compensation arrangement from Martine Rothblatt, with 294,000 shares acquired at that time.